BRCA1 and breast carcinoma: This finding is concordant with results of the INFORM trial, which showed equivalent response of BRCA1/2-associated breast cancers to several different chemotherapy agents (7): taken together, they suggest that comparison of different chemotherapy drugs should not be a major focus of future clinical trials in BRCA1/2-associated TNBC.